Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of$ 0.37. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.92%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of$ 0.48 per share when it actually produced a loss of $0.41, delivering a surprise of 14.58%.Over the last four quar ...